InvestorsHub Logo
Followers 13
Posts 1546
Boards Moderated 0
Alias Born 06/14/2018

Re: None

Monday, 06/12/2023 8:32:52 AM

Monday, June 12, 2023 8:32:52 AM

Post# of 34625
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial.
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-announces-first-lymphoma-patient-treated-mt
The first patient in the APOLLO trial recently received MT-601 at the 200 million cell dose level. This patient was monitored for 18 days after being dosed and showed no treatment-related adverse events, indicating that the therapy was well tolerated.
Under the APOLLO trial, eight clinical sites across the United States will cumulatively enroll up to 30 patients during the dose escalation phase.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News